{"name":"NEURONOSTICS LIMITED","company_number":"11123728","status":"Active","type":"Private Limited Company","incorporated":"2017-12-22","dissolved":null,"registered_office":"Science Creates Old Market, Midland Road, Bristol, England, BS2 0NS","postcode":"BS2 0NS","sic_codes":[{"code":72190,"description":"Other research and experimental development on natural sciences and engineering"}],"principal_activity":"The principal activity of the company is that of the development of biomarkers from human brain data that can support neurologists and clinical scientists in the diagnosis and management of neurological conditions.","previous_names":[],"warnings":[],"accounts":{"category":"Total Exemption Full","year_end":"31 December","last_made_up_to":"2025-12-31","next_due":"2027-09-30"},"employees":{"count":17,"accounts_date":"2025-12-31"},"financials":[{"financial_date":"2025-12-31","turnover":300367,"profit_loss":-595063,"average_employees":17},{"financial_date":"2024-12-31","turnover":104388,"profit_loss":-455130,"average_employees":13},{"financial_date":"2023-12-31"},{"financial_date":"2022-12-31","net_assets":70090,"cash":96796},{"financial_date":"2021-12-31","net_assets":429008,"cash":341699}],"officers":{"current":6,"resigned":4,"complete":true,"note":"Names and details of individual officers are on the People page (subscriber-only on this site) and free at Companies House."},"charges":{"total":0,"outstanding":0},"gazette_notices":[],"insolvency_outcome":null,"ai_summary":"Neuronostics represents a high-potential, early-commercialization-stage medtech company with defensible IP in computational neurodiagnostics and a leadership team positioned for international expansion. The tripling of revenue in FY2025 validates market demand, whilst the deepening R&D investment and appointment of US-based leadership signal preparation for a significant growth phase. However, the widening operating losses and funding dependency create execution risk that must be managed through disciplined prioritization of regulatory pathways, strategic partnerships, and capital efficiency—success will ultimately depend on converting scientific capability into reimbursable clinical products faster than the cash runway depletes.","website":"https://www.neuronostics.com/","links":{"page":"https://www.companiesintheuk.co.uk/ltd/neuronostics","people":"https://www.companiesintheuk.co.uk/company/neuronostics/people","filing_history":"https://www.companiesintheuk.co.uk/company/neuronostics/filing-history","companies_house":"https://find-and-update.company-information.service.gov.uk/company/11123728","financials":"https://www.companiesintheuk.co.uk/company/neuronostics/financial","control":"https://www.companiesintheuk.co.uk/company/neuronostics/control","ai_analysis":"https://www.companiesintheuk.co.uk/company/neuronostics/analysis"},"source":"CompaniesInTheUK, from Companies House, The Gazette and other public registers (see /support/about). Cite as: CompaniesInTheUK, https://www.companiesintheuk.co.uk/ltd/neuronostics"}